Next Phase Newsletter

A corporate venture fund headquartered in USA has 7 active portfolio companies and 1 exit. The fund’s typical check size is between $1-10M, with flexibility for follow-on investments. The fund focuses on US-based  companies and/or companies with US traction.

The firm is interested in tech-enabled services (addressing renal co-morbidities such as diabetes, cardiology, pulmonology, etc.), digital health (addressing patient or physician engagement), and renal IP (including diagnostics and non-invasive medical devices).

The firm is open to all types of management teams, but have a preference for entrepreneurial experience. The firm likes to typically see at least $1M in ARR for digital health and tech-enabled services companies. The firm prefers to join syndicates vs lead rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading venture capital firm dedicated to building next generation companies in the healthcare sector is focused on the cell and gene therapy and regenerative medicine sector and will consider opportunities encompassing therapeutics, diagnostics, and those harnessing data to revolutionize the sector. The firm partners with passionate teams that are backed by strong scientific platforms and will primarily invest in preclinical stage assets, contributing $1 – 2M initially. With operations in Japan and the United States, the fund takes a global approach to building value in their portfolio by linking these two important life science markets and leveraging the respective advantages of each ecosystem.

The firm invests exclusively in technologies relating to cell therapy and regenerative medicine, including precision medicine tools and discovery of new treatment modalities. The company can be in therapeutics, diagnostics or digital health. The firm’s primary areas of interest are oncology, autoimmune disorders, CNS, cardiovascular, renal and liver.

Most of the firm’s investments are in companies either located or looking to enter the Japanese market. The firm can lead or co-invest, and will generally take a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm in Western Europe has supported over 80 companies and actively works as an active collaborator in the life sciences industry by the means of co-creation of companies, capital acquisition, and more. The firm has a network of hospitals in which allows the firm to help companies better develop health products that meet patient needs. Notably, it has organized an operational team of Experts and Entrepreneurs in residence enabling hands-on activities. When investing, the firm will likely combine between €2-7M, depending on the company’s needs, and focuses on partnering with seed and early venture stage companies. The firm is open to working with companies beyond Western Europe, including USA, Canada, and other geographies with sizable markets.

The firm is most interested in medical devices and diagnostics companies. While the firm is agnostic in terms of stage of development or disease areas/indications, the firm is seeking technologies that can be implemented in hospital systems in the short term (~4-5 years). The firm is also open to digital health technologies but stays away from traditional therapeutics.

The firm seeks to work with experienced, dedicated management teams. The firm seeks to be a very active, hands-on partner with all companies they work with, assisting companies with services such as operations, management team support, etc. As an active health innovation integrator, the firm also helps organize regular networking events to foster new connections and collaborations among their network of entrepreneurs, investors, industry partners, and more. The firm can act as a lead or co-investor depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the US manages a total of $85 million in assets and is currently making investments out of its vintage 2017 fund. The firm is raising Fund IV that will close in the third quarter of 2023, and anticipates an additional $50 million of assets under management. The firm provides from $1-$7 million of its own capital to chosen companies and can leverage its network of investors to provide up to $10 million over the life of the investment. The firm looks to invest in companies located in the US except for NYC north and Silicon Valley north and plans to invest in 2-3 companies over the next year.

The firm is looking for Life Science companies primarily in areas of Medical Technology, Diagnostics and B2B Digital Health although the firm will also consider companies with developed and approved therapeutics. The firm is open to all subsectors and indications within these areas but prefers orthopedics and cardiovascular.

Ideal companies have $1 million or more of run-rate revenue; gross margins of 50% or higher; and equity capital needs of less than $10 million at the time of investment. The firm looks to take a board seat into companies and take a very active role in helping the company expand through their network of strategic partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in Canada looks to invest in clinical stage medical devices and diagnostics technologies as well as digital health companies. The firm looks to invest in companies with large market opportunities. The firm prefers to invest in Canadian companies, but will consider companies outside of Canada if they wish to expand to the Canadian market. The firm prefers to co-invest alongside other investors, and will invest $100,000-$250,000 in the initial investment, potentially contributing to additional rounds of funding.

The firm is looking for device companies, either in the medical device or diagnostic space. The firm will also consider digital health companies, focusing on mobile applications. For devices and diagnostics, the firm prefers 510k devices, but will consider PMA devices as well. These devices should be in the clinical development phase. The firm is indication agnostic, but does look for there to be a large market potential.

The firm looks for companies with strong management teams with good team dynamics, although previous entrepreneurial experience is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund founded in 2015 and based in China closed its second fund at ¥100M that again focuses on opportunities in China. The firm invests in early-stage life science ventures from Seed to Series A. Typical initial size of investment ranges from $500k-1M USD.

The firm will consider medical devices especially minimally invasive medical devices, and diagnostics. Within medical devices, the fund is interested in 510k and software-enabled devices and looks at the in-development phase (must include proof of concept). Particularly, the firm is interested in devices related to digital technology such as artificial intelligence. Within diagnostics, the firm is interested in in-vitro diagnostics that are in-development. The main indication areas of interest are heart disease, infectious disease, chronic disease, and rehabilitation.

The firm prefers to work with a management team with established industry partners. The fund also prefers the CEO to have expertise in the respective life science fields. The fund is open to both leading and co-investing and will not require board seating. Although it has a China focus, the fund has supporting partners who are able to work with offshore companies that are interested in attaining proof of concept in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 and is headquartered in the USA. The firm currently manages 3 funds, and also has an advisory business that is solely dedicated for companies trying to enter the Asian market. The firm has a focus on early-stage investments (pre-Series A to Series B) and has portfolio companies spread over the USA. The firm’s initial investment size varies, but typically falls under the $250K – 2.5M range and is dedicated to follow-on financings of existing portfolio companies. The firm invests only in USA and Canada.

Within life sciences/healthcare, the firm is most interested in medical devices and smart manufacturing in life sciences, and is much more selective when it comes to biotech or therapeutics investments. Most importantly, the firm is focused on assessing the company’s patent status and the degree of novelty. While the firm is agnostic to stage of development, ideally the companies should have a working prototype and significant key data that validates the high potential of their technology. In terms of different types of technologies or diseases areas/indications, the firm is opportunistic.

The firm has no specific management team requirements, but considers patent strategy key in reviewing potential investments. Companies should have key patents issued or a clear strategy on improving their IP portfolio. The firm has great expertise in helping USA/Canada-based companies enter Asian markets (i.e. greater China) and extend their IP coverage. The firm can act as either lead or co-investor and will seek a board seat if they come in as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.